Abstract:BACKGROUND:Recently, some studies have showed that miR-200 families act as novel biomarkers for the prediction of cancer outcomes. AIMS:This meta-analysis was designed to investigate the associations between miR-200 families and the prognosis of patients with various cancers. MATERIALS & METHODS:Eligible published databases including PubMed, Embase and Chinese National Knowledge Infrastructure (CNKI) databases were searched for articles until October 18, 2016. We performed a meta-analysis by calculating pooled hazard ratios (HR) and 95% confidence intervals (CI). Data were extracted from studies comparing overall survival (OS), progression-free survival (PFS) or recurrence-free survival (RFS). RESULTS:For OS, the pooled HR was 1.54 (95% CI: 1.01-2.33), showing that high miR-200 family was clearly related to poor survival in various carcinomas, but no significantly association was found in PFS or RFS. Subgroup analysis indicated that upregulated miR-200 family was linked to poor OS in Asians (HR = 2.19, 95% CI: 1.27-3.78) but not in Caucasians (HR = 0.94, 95% CI: 0.46-1.91). Similarly, high miR-200 expression could not clearly predict the relationship with PFS and RFS. For cancer type, high miR-200 also predicted poor OS among lung cancer patients (HR = 3.09, 95% CI: 1.75-5.46). Besides, only elevated miR-200c of the miR-200 family indicated a significantly poor OS (HR = 2.25, 95% CI: 1.39-3.64). DISCUSSION:Aberrant expression of miRNAs played a crucial role in the area of human carcinomas. Many studies have indicated that miRNAs are considered promising tumor biomarkers for prognosis and potential targets for clinical treatment. We have testified that high levels of miR-200 family expression (predominantly miR-200c) are significantly associated with poor survival and prognostic outcomes of patients with cancers, especially in lung cancer. However, no statistically significant results were calculated for miR-200a/b and miR-429, and this might result from a relatively small number of articles about them. In other tumor models except lung cancer, our results indicated that high miR-200 family was not obviously associated with OS (Gastric or Colorectal cancer; Ovarian cancer; Others). In addition, some other records showed the opposite results, for they exhibited that upregulated miR-200 family level was linked to longer survival. For ethnic group, our stratified analyses showed that the Asian population predicted poor OS. While the Caucasian population did not exhibit an significant association with OS. This discrepancy might result from different hereditary backgrounds and environment exposure. Although these results have indicated that miR-200 families were promising biomarkers to predict prognosis for patients with cancers, there were several limitations in this analysis that would impact its quality. Generally, further studies should be warranted to clarify this question and to provide a new novel idea for routine clinical application. CONCLUSION:Our findings suggest that miR-200 family might be a potentially useful biomarker for predicting cancer prognosis, especially for lung cancer in Asians.

DNA microarrays are predictive of cancer prognosis: a re-evaluation.

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to Be Placed in the Context of Clinical Reality-Response

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

Shifting From Population-Wide To Personalized Cancer Prognosis With Microarrays

Outcome prediction based on microarray analysis: a critical perspective on methods

Refute the conclusion made by Jie et al. in “Prognostic role of microRNA-100 in various carcinomas: evidence from six studies”

A two step method to identify clinical outcome relevant genes with microarray data.

Using Micrornas As Novel Predictors of Urologic Cancer Survival: an Integrated Analysis.

Derivation of stable microarray cancer-differentiating signatures using consensus scoring of multiple random sampling and gene-ranking consistency evaluation.

Integrative analysis of multiple cancer prognosis studies with gene expression measurements.

Comparative analysis of oncogenes identified by microarray and RNA-sequencing as biomarkers for clinical prognosis.

On the statistical assessment of classifiers using DNA microarray data

Molecular Signature of Cancer at Gene Level or Pathway Level? Case Studies of Colorectal Cancer and Prostate Cancer Microarray Data.

Identifying Oncogenes As Features for Clinical Cancer Prognosis by Bayesian Nonparametric Variable Selection Algorithm

Microarray-based Cancer Prediction Using Single Genes

Converting a Microarray Signature into a Diagnostic Test: A Trial of Custom 74 Gene Array for Clarification and Prediction the Prognosis of Gastric Cancer

The Prognostic Value of the MiR-200 Family in Colorectal Cancer: A Meta-analysis with 1882 Patients.

Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts

MicroRNA-200 Families and Prognostic Value in Various Carcinomas: A Systematic Review and Meta-Analysis.

Comparison of RNA-Seq and microarray in the prediction of protein expression and survival prediction

Gene expression profiling of breast cancer survivability by pooled cDNA microarray analysis using logistic regression, artificial neural networks and decision trees